AYTU Profile
Aytu Biopharma, Inc., headquartered in Englewood, Colorado, is a specialty pharmaceutical company that is actively engaged in the development and commercialization of innovative therapeutics and consumer healthcare products. Founded in 2015 and previously known as Aytu BioScience, Inc. before its rebranding in March 2021, the company operates both domestically in the United States and internationally, focusing on addressing significant unmet medical needs across various therapeutic areas.
The company’s portfolio includes a range of products designed to treat and manage specific health conditions. Aytu Biopharma’s flagship product, Adzenys XR-ODT, is an extended-release orally disintegrating tablet used for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged six years and older. Additionally, Cotempla XR-ODT is another extended-release formulation aimed at managing ADHD, specifically for patients between the ages of six and seventeen. These products highlight Aytu Biopharma's commitment to providing effective and convenient treatment options for managing ADHD.
In the area of allergy management, Aytu Biopharma offers Karbinal ER, an extended-release oral suspension formulated with carbinoxamine to alleviate symptoms of seasonal and perennial allergies. The company also provides Poly-Vi-Flor and Tri-Vi-Flor, prescription supplements designed to address fluoride deficiency in infants and children. These supplements play a critical role in preventing dental issues related to fluoride deficiency, underscoring the company's focus on pediatric health.
Aytu Biopharma’s broad range of therapeutic and consumer healthcare products reflects its dedication to addressing diverse medical needs through innovation and strategic development. By leveraging its expertise in specialty pharmaceuticals and consumer health, the company is well-positioned to make significant contributions to patient care and health management on a global scale. The company’s ongoing efforts to expand and enhance its product offerings demonstrate its commitment to improving health outcomes and addressing critical health challenges.
|
